Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Nerdwallet Inc (NRDS) vs Novartis AG (NVS) Price & Performance

Nerdwallet IncTrade
Novartis AGTrade

Price performance (Past 24H)

Key statistics

Nerdwallet Inc vs Novartis AG — how do they compare? Nerdwallet Inc trades at $9.68 (market cap $625.17M), while Novartis AG trades at $143.75 (market cap $268.57B). The key difference: Novartis AG is far larger — about 429.6× Nerdwallet Inc's market cap, and Novartis AG pays a 3.31% dividend while Nerdwallet Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nerdwallet Inc for 45 Days and Novartis AG for 82 Days on average.

NRDSNVS
Market Cap
$625.17M$268.57B
Volume
1,321,3161,532,573
Sector
MediaHealth
52-Week High
$15.93$168.62
52-Week Low
$7.58$121.80
Typical Hold Time
45 Days82 Days
Enterprise Value
$539.47M$309.89B
Dividend Yield
—3.31%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Nerdwallet Inc

NerdWallet (NRDS) trades at $9.82, up 8.04% with strong technical momentum. The company shows improving fundamentals with 2025 revenue reaching $836.6M and net income of $48.7M, representing a 5.82% margin. Recent earnings beat expectations in Q4 2025 and Q1 2026, though Q2 2026 missed estimates. Valuation metrics appear attractive with P/E of 10.87 and P/S of 0.81. Analyst sentiment remains positive with 66.7% buy ratings and technical indicators signaling bullish momentum.

The outlook remains constructive as NerdWallet demonstrates revenue growth acceleration and margin expansion. Key risks include organic search pressure in credit card products and macroeconomic sensitivity. With strong cash flow generation and institutional support, the stock offers growth potential at reasonable valuations, though investors should monitor competitive pressures and execution on guidance.

Novartis AG

Novartis (NVS) trades at $143.22, down 0.04% on the day, near the analyst consensus price target of $146. The stock shows mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company reported strong 2025 revenue of $56.67B and net income of $13.98B, with a robust net margin of 24.67%. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though this follows clinical setbacks in other drug programs.

The outlook is cautiously optimistic. The Abogen deal expands the pipeline in autoimmune diseases, a growth area, and analyst consensus leans Hold with a slight upside to the price target. Key risks include integration challenges from recent acquisitions, pipeline volatility after trial failures, and investor scrutiny over M&A strategy. Earnings momentum is mixed, with a recent beat in Q2 but a miss in Q1, requiring consistent execution to justify current valuations.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

NRDS
0% Buy100% Sell
Avg holding period · 45 Days
NVS
0% Buy100% Sell
Avg holding period · 82 Days

Top news

Latest headlines on both assets

About Nerdwallet Inc

Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.

Read more on NRDS →

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS →